AstraZeneca PLC (ZEG.DE) is preparing for its earnings announcement on April 29, 2026. The biopharmaceutical giant trades at €160.70 with a market cap of $249.22 billion. The company focuses on oncology, cardiovascular, respiratory, and rare disease treatments. AstraZeneca earnings reports typically attract significant investor attention. The pharmaceutical sector watches closely for revenue trends and pipeline progress. Meyka AI rates ZEG.DE with a grade of B+, reflecting neutral sentiment. Investors should monitor how the company’s latest results compare to previous quarters.
AstraZeneca Stock Performance and Valuation
AstraZeneca shares have shown steady momentum heading into earnings. The stock trades near its 50-day average of €159.81. Year-to-date performance stands at 2.78%, while the 52-week range spans €111.00 to €166.30.
Current Trading Metrics
The stock closed at €160.70 with a P/E ratio of 28.75. This valuation sits above historical averages for the sector. Price-to-sales ratio of 4.99 reflects premium positioning. The company maintains a dividend yield of 1.69%, attractive for income investors. Trading volume averaged 6,135 shares daily, with recent activity at 14,221 shares.
Market Capitalization and Scale
With $249.22 billion in market cap, AstraZeneca ranks among global pharma leaders. Enterprise value reaches $317.27 billion, accounting for net debt. The company operates with 943,000 full-time employees worldwide. Strong balance sheet metrics support ongoing research investments. Debt-to-equity ratio of 0.61 remains manageable for the sector.
Financial Health and Key Metrics
AstraZeneca demonstrates solid financial fundamentals across multiple indicators. The company generates strong cash flows supporting dividends and R&D spending. Recent trailing twelve-month data reveals operational strength and profitability.
Profitability and Margins
Net profit margin stands at 17.41%, showing efficient cost management. Operating margin reaches 23.40%, indicating strong core business performance. Gross margin of 81.79% reflects pricing power in key markets. Return on equity of 22.68% exceeds many industry peers. Free cash flow per share totals €6.26, supporting shareholder returns.
Balance Sheet Strength
Current ratio of 0.94 indicates tight working capital management. Cash per share reaches €3.70, providing liquidity cushion. Interest coverage of 8.48 times shows comfortable debt servicing ability. The company maintains €3.19 dividend per share, up 4.1% year-over-year. Debt-to-assets ratio of 0.26 reflects conservative leverage.
Growth Trajectory and Forward Outlook
AstraZeneca shows consistent growth across revenue and earnings metrics. Recent financial growth demonstrates the company’s expansion momentum. Pipeline strength and market expansion drive positive momentum.
Revenue and Earnings Growth
Full-year revenue growth reached 13.65%, accelerating from prior periods. Gross profit grew 15.24%, outpacing revenue expansion. Operating income surged 30.85%, reflecting operational leverage. Net income increased 13.75%, translating to EPS growth of 13.55%. Operating cash flow grew 14.65%, supporting reinvestment capacity.
Long-Term Growth Prospects
Three-year revenue growth per share stands at 30.53%. Five-year net income growth per share totals 331%, showing exceptional expansion. Three-year operating cash flow growth reaches 81.97%. Dividend per share grew 9.82% over three years. These metrics signal strong competitive positioning and market share gains.
Technical Analysis and Market Sentiment
Technical indicators suggest balanced momentum as earnings approach. The stock shows neither overbought nor oversold conditions. Trend strength remains moderate with mixed signals from oscillators.
Trend and Momentum Indicators
RSI at 53.21 indicates neutral positioning without extreme conditions. MACD histogram of 0.37 shows positive momentum building. ADX at 25.99 confirms a strong trend in place. Stochastic %K at 73.87 suggests upward pressure. Williams %R at -28.57 indicates room for further gains.
Volatility and Support Levels
Average true range of €2.67 shows moderate daily volatility. Keltner Channel middle line sits at €159.79, near current price. Upper channel at €165.13 provides resistance target. Lower channel at €154.45 offers support level. Recent trading within these bands suggests consolidation phase before earnings.
Final Thoughts
AstraZeneca PLC approaches its April 29 earnings announcement with strong fundamentals and solid momentum. The company’s €160.70 stock price reflects a $249.22 billion market cap and premium valuation. Financial metrics show 13.65% revenue growth, 30.85% operating income growth, and 22.68% return on equity. Meyka AI rates ZEG.DE with a B+ grade, suggesting neutral positioning. Investors should focus on pipeline progress, revenue trends, and forward guidance when results release. The pharmaceutical leader’s consistent profitability and cash generation support long-term shareholder value.
FAQs
When does AstraZeneca report earnings?
AstraZeneca announces earnings on April 29, 2026 at 3:30 PM UTC, providing detailed financial results, management commentary, and guidance for upcoming quarters.
What is AstraZeneca’s current stock price and market cap?
ZEG.DE trades at €160.70 with $249.22 billion market cap, P/E ratio of 28.75, dividend yield of 1.69%, and year-to-date performance of 2.78%.
What does Meyka AI rate AstraZeneca?
Meyka AI rates ZEG.DE as B+, indicating neutral sentiment. Strong profitability and cash flow support the rating, reflecting balanced fundamentals with both strengths and concerns.
How has AstraZeneca grown recently?
Full-year revenue grew 13.65%, operating income surged 30.85%, net income increased 13.75%, and EPS grew 13.55%. Operating cash flow expanded 14.65%, supporting dividends and R&D.
What are AstraZeneca’s main business segments?
AstraZeneca operates in oncology, cardiovascular, respiratory, and rare disease treatments. Key products include Tagrisso, Lynparza, and Symbicort, with 943,000 employees globally.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)